Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 9/20 | 0.61 |
| ▸ | ATP4B | P51164 | 9/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | C1S | P09871 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | GSTO1 | P78417 | 3/20 | 0.46 |
| ▸ | MRE11 | P49959 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660073 | 0.84 | GSTO1 (0.64) | ATP4AATP4BGSTO1LMNATHRB | |
| SCHEMBL3609963 | 0.84 | GSTO1 (0.61) | ATP4AATP4BGSTO1 | |
| SCHEMBL3612827 | 0.84 | ATP4A (0.47) | ATP4AATP4BPLAUGSTO1LMNA | |
| SCHEMBL3608371 | 0.84 | GSTO1 (0.64) | ATP4AATP4BGSTO1LMNATHRB | |
| SCHEMBL11239260 | 0.84 | ATP4A (0.47) | ATP4AATP4BSIRT5PLAUGSTO1 | |
| SCHEMBL3602268 | 0.83 | MAPT (0.56) | ATP4AATP4BPLAULMNA | |
| SCHEMBL3610620 | 0.83 | ATP4A (0.49) | ATP4AATP4BPLAUGSTO1 | |
| SCHEMBL10809913 | 0.82 | MAPT (0.57) | ATP4AATP4BSIRT5GSTO1MRE11 | |
| SCHEMBL10955195 | 0.82 | ATP4A (0.57) | ATP4AATP4BSIRT5GSTO1MRE11 | |
| SCHEMBL3600274 | 0.82 | VCP (0.64) | ATP4AATP4BC1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ATP4A 996/4885ATP4B 1107/4885SIRT5 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.